1. Home
  2. CAC vs CGEM Comparison

CAC vs CGEM Comparison

Compare CAC & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Camden National Corporation

CAC

Camden National Corporation

HOLD

Current Price

$50.13

Market Cap

857.1M

Sector

Finance

ML Signal

HOLD

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$16.35

Market Cap

904.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CAC
CGEM
Founded
1875
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
857.1M
904.7M
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
CAC
CGEM
Price
$50.13
$16.35
Analyst Decision
Buy
Strong Buy
Analyst Count
2
8
Target Price
$47.00
$30.13
AVG Volume (30 Days)
77.4K
956.5K
Earning Date
04-28-2026
05-11-2026
Dividend Yield
3.51%
N/A
EPS Growth
6.08
N/A
EPS
1.29
N/A
Revenue
$41,739,000.00
N/A
Revenue This Year
$19.15
N/A
Revenue Next Year
$6.05
$5.20
P/E Ratio
$38.62
N/A
Revenue Growth
16.96
N/A
52 Week Low
$35.00
$5.68
52 Week High
$53.71
$16.74

Technical Indicators

Market Signals
Indicator
CAC
CGEM
Relative Strength Index (RSI) 58.30 62.01
Support Level $47.12 $11.92
Resistance Level $51.57 N/A
Average True Range (ATR) 1.07 1.03
MACD 0.21 0.08
Stochastic Oscillator 77.44 89.05

Price Performance

Historical Comparison
CAC
CGEM

About CAC Camden National Corporation

Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Share on Social Networks: